ArticleFrontiers in medicine2025
Central obesity in psoriatic arthritis: associations with disease activity, function, and quality of life in a real-world cohort.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Body Mass Index Is Associated with the Immunometabolic Profile in Psoriatic Arthritis: Real-Life Data.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the association between central obesity and disease-specific activity, functional impairment, and patient-reported outcomes (PROMs) in a real-world cohort of individuals with psoriatic arthritis (PsA). Methods: We conducted a cross-sectional observational study at a tertiary rheumatology outpatient clinic. Adult patients with PsA, diagnosed according to the CASPAR criteria, underwent a multidimensional assessment by a multidisciplinary team. Clinical and pharmacological data, anthropometric measures, disease activity indices (DAPSA and CRP), and PROMs (FACIT-F, PHQ-9, HAQ, PsAID) were collected. Central obesity was defined by waist circumference (≥88 cm in women, ≥102 cm in men). Multivariable regression analyses were performed to investigate associations between central obesity and clinical outcomes, adjusting for age, sex, disease duration, and antirheumatic therapies. Results: Among 158 patients (54.4% female; median age 55.4 years), central obesity was present in 70.2% of the group. Patients with central obesity had significantly higher inflammatory markers (CRP), increased disease activity (DAPSA), and worse scores across all PROMs compared to those without. In multivariable models, central obesity remained independently linked to disease activity and worse physical and psychosocial outcomes, including fatigue, depression, disability, and disease impact. Conclusion: Central obesity is a significant and independent predictor of disease severity and patient-reported disability in individuals with Psa. These findings highlight the clinical importance of routinely measuring waist circumference in PsA management and suggest that targeted interventions addressing visceral adiposity could enhance both inflammatory and quality-of-life outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.